These results suggest that BCL-xL upregulation is presented in HCC tumors and is frequently associated with a parallel MCL-1 reduction, a feature that could help A-1331852 anti-tumoral activity. The gene discussed is BCL2L1; the disease is hepatocellular carcinoma.